Form 4 for RNAZ Transcode Therapeutics, Inc.
Accepted 2023-06-22 00:00:00 ET · period of report 2023-06-20 · accession 0001104659-23-073872 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-06-22 | 2023-06-20+ | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.61 | +18.6K | 70.3K | +36% | +$48.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-21 | P | A | 12,000 | $2.65 | 82,262 | D | — | — | (F2) Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2023-06-20 | P | A | 6,607 | $2.55 | 70,262 | D | — | — | (F1) Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. |